Corline Biomedical
7.06
SEK
-2.49 %
CLBIO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
-2.49%
-11.75%
-19.77%
-35.82%
-52.62%
-50.46%
-49.03%
-53.01%
-28.63%
www.corline.se/investors
Corline Biomedical operates in the pharmaceutical industry. The company develops with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The drug candidates are based on the same basic technology as the medical technology products. Corline Biomedical operates on the Nordic market and is headquartered in Uppsala.
Revenue
25.03M
EBIT %
-7.15 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CLBIO
Daily low / high price
6.98 / 7.36
SEK
Market cap
172.91M SEK
Turnover
129.08K SEK
Volume
18K
Financial calendar
Annual report
17.02.2025
Interim report
08.05.2025
Interim report
26.08.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Adam Dahlberg | 26.7 % | 26.7 % |
Eccenovo AB | 8.6 % | 8.6 % |
HealthInvest Microcap Fund AB | 8.5 % | 8.5 % |
Annika Sunnanväder | 5.8 % | 5.8 % |
M2 Asset Management AB | 4.3 % | 4.3 % |
Monika Sunnanväder | 4.0 % | 4.0 % |
Thomas Krishan | 3.7 % | 3.7 % |
Margareta Nilsson | 2.9 % | 2.9 % |
Henrik Nittmar genom bolag | 2.6 % | 2.6 % |
Thomas Olausson | 1.3 % | 1.3 % |
ShowingAll content types
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools